Donanemab Clinical Use Growing in U.S., Rejected in Europe
Donanemab prescriptions have been slow to ramp up, but demand is growing due to an easier dosing schedule than for lecanemab.
Donanemab prescriptions have been slow to ramp up, but demand is growing due to an easier dosing schedule than for lecanemab.
Healthy people who carry an autosomal-dominant AD mutation halved their odds of developing symptoms when they took gantenerumab for eight years.
Core structures of protofilaments from more diseases prompt an update to the family tree of tau filaments.
Dementia prevalence has come down nearly 3 percent per year for the last 40 years, with each successive birth cohort less likely to succumb.
In the largest study of its kind, volunteers took cognitive tests on their devices and had their app usage monitored. Baseline data flagged people with MCI.
People who ate a healthy diet and carried less abdominal fat in midlife had better-working brains 20 years later, according to MRI scans.
P-tau181 and p-tau217 are AD biomarkers, but they are also found in blood and muscles of people with ALS.
A large meta-analysis turns up 16 new loci.
For the past several months, Alzheimer’s scientists have been concerned about a New York Times essay and subsequent book criticizing their field. The book’s timing during the change of administration in the U.S., and the actions of DOGE, has rendered the conversation mostly private, as scientists fear for their grants and jobs. Several attempts to publicly refute the claims were rebuffed. A Viewpoints article published March 17 in JAMA online elicited discussion on Alzforum. Thus far, 10 leading scientists from the U.S. and Europe have spoken their minds.
Over the past eight years, cryo-electron microscopy has unveiled a stunning array of tau filament folds that lurk in the brains of people with different tauopathies, allowing scientists to classify them in a tau family tree. As more structures have come onto the scene, scientists now present an updated version, identifying AD-like tau folds in some forms of FTD, and spotting CTE-folds in a trio of other diseases.
Could predictions of a doubling of U.S. dementia cases by 2050 be overblown? A provocative new analysis suggests so, finding that the age-adjusted prevalence of dementia has dropped by two-thirds in the last 40 years as public health improved. That projects to only 25 percent more dementia in 2050, even with an aging population. Will positive health trends continue, or will rising obesity and diabetes reverse them?
New in last 7 days
Latest Comments